Kong Jian, Gao Ruize, Wu Shilun, Shi Yaoping, Yin Tao, Guo Shigang, Xin Zonghai, Li Aolei, Kong Xinliang, Ma Demin, Zhai Bo, Sun Wenbing, Gao Jun
Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital Affiliated To Capital Medical University, Beijing, 100043, China.
Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200120, China.
Eur Radiol. 2022 May;32(5):3309-3318. doi: 10.1007/s00330-021-08425-4. Epub 2022 Jan 29.
To compare the safety and efficacy of microwave ablation (MWA) and radiofrequency ablation (RFA) for such hemangiomas (5-9.9 cm in diameter).
This multicenter retrospective cohort study investigated the differences in technical success, ablation time, complete ablation, complications, hospital stay, and clinical response between MWA and RFA. A total of 452 patients with hepatic hemangiomas were screened. Propensity score matching was performed. Univariable and multivariate regression analyses were used.
Among the 452 patients, 394 met the eligibility criteria and completed the follow-up. After the propensity score matching analysis, 72 pairs of patients were created. No technical failures were found. The RFA group had a longer ablation time (48.63 ± 18.11 min versus [vs.] 37.18 ± 15.86 min, p < 0.001), higher morbidity of hemoglobinuria (77.78% vs. 50.00%, p < 0.001), and longer hospital stay (5.01 ± 1.56 days vs. 4.34 ± 1.42 days, p < 0.05) than the MWA group. The treatment methods (p = 0.032, OR = 0.105, 95% CI = 0.013-0.821), size of the hemangioma (p = 0.021, OR = 5.243, 95% CI = 1.285-21.391), and time of ablation (p = 0.031, OR = 1.145, 95% CI = 1.013-1.294) were significant independent risk factors associated with hemoglobinuria. No recurrence or delayed complications were observed. There were no differences in complete ablation, clinical response, and health-related quality of life between the groups.
MWA and RFA appear to be effective treatments for large hepatic hemangiomas. However, MWA had a shorter ablation time than RFA, and MWA was associated with fewer hemolysis-related complications and shorter hospital stays.
• MWA and RFA appear to be effective treatments for large hepatic hemangiomas. • MWA had a shorter ablation time than RFA. • MWA was associated with fewer hemolysis-related complications and shorter hospital stays.
比较微波消融(MWA)和射频消融(RFA)治疗直径5 - 9.9厘米的此类肝血管瘤的安全性和有效性。
这项多中心回顾性队列研究调查了MWA和RFA在技术成功率、消融时间、完全消融、并发症、住院时间和临床反应方面的差异。共筛选了452例肝血管瘤患者。进行倾向得分匹配。采用单变量和多变量回归分析。
452例患者中,394例符合纳入标准并完成随访。倾向得分匹配分析后,创建了72对患者。未发现技术失败情况。RFA组的消融时间更长(48.63±18.11分钟对37.18±15.86分钟,p<0.001),血红蛋白尿发病率更高(77.78%对50.00%,p<0.001),住院时间更长(5.01±1.56天对4.34±1.42天,p<0.05)。治疗方法(p = 0.032,OR = 0.105,95%CI = 0.013 - 0.821)﹑肝血管瘤大小(p = 0.021,OR = 5.243,95%CI = 1.285 - 21.391)和消融时间(p = 0.031,OR = 1.145,95%CI = 1.013 - 1.294)是与血红蛋白尿相关的显著独立危险因素。未观察到复发或延迟并发症。两组在完全消融、临床反应和健康相关生活质量方面无差异。
MWA和RFA似乎都是治疗大型肝血管瘤的有效方法。然而,MWA的消融时间比RFA短,且MWA与较少的溶血相关并发症和较短的住院时间相关。
• MWA和RFA似乎都是治疗大型肝血管瘤的有效方法。• MWA的消融时间比RFA短。• MWA与较少的溶血相关并发症和较短的住院时间相关。